tiprankstipranks
Viatris wins court decision invalidating AstraZeneca’s Symbicort patent
The Fly

Viatris wins court decision invalidating AstraZeneca’s Symbicort patent

Viatris (VTRS), a global healthcare company announced that it and Kindeva Drug Delivery L.P. have won a significant court decision in which the U.S. District Court for the Northern District of West Virginia found that AstraZeneca’s (AZN) Symbicort patent, U.S. Patent No. 10,166,247, is invalid. The district court determined that the patent is invalid on two separate grounds – lack of written description and lack of enablement. Viatris President Rajiv Malik said: "We are extremely pleased with the court’s decision as it clears away yet another of AstraZeneca’s invalid patents, which have only served to block generic versions and delay access to this important product for American patients. This affirms Viatris’ continuing efforts to break down barriers to patient access for important medicines. We already have FDA approval for our generic Symbicort product, and we look forward to the opportunity to bring our more affordable product to market."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on VTRS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles